Highview Capital Management LLC Vertex Pharmaceuticals Inc Transaction History

Highview Capital Management LLC

$233 Million
Q1 2025

A detailed history of Highview Capital Management LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Highview Capital Management LLC holds 5,917 shares of VRTX stock, worth $2.62 Million. This represents 1.23% of its overall portfolio holdings.

Number of Shares

5,917

Previous 5,771 2.53%

Holding current value

$2.62 Million

Previous $2.32 Million 23.46%

% of portfolio

1.23%

Previous 0.91%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 30, 2025	BUY	$402.49 - $513.76 $58,763 - $75,008	146 Added 2.53%	5,917 $2.87 Million
Q4 2024 Jan 31, 2025	BUY	$396.64 - $516.74 $40,457 - $52,707	102 Added 1.8%	5,771 $2.32 Million
Q3 2024 Oct 25, 2024	BUY	$460.0 - $505.78 $61,640 - $67,774	134 Added 2.42%	5,669 $2.64 Million
Q2 2024 Jul 29, 2024	BUY	$392.81 - $485.53 $43,209 - $53,408	110 Added 2.03%	5,535 $2.59 Million
Q1 2024 Apr 26, 2024	BUY	$407.69 - $446.08 $141,060 - $154,343	346 Added 6.81%	5,425 $2.27 Million
Q4 2023 Jan 29, 2024	BUY	$343.0 - $410.68 $41,503 - $49,692	121 Added 2.44%	5,079 $2.07 Million
Q3 2023 Oct 20, 2023	SELL	$338.18 - $362.46 $2,367 - $2,537	-7 Reduced 0.14%	4,958 $1.72 Million
Q2 2023 Jul 19, 2023	BUY	$314.42 - $351.91 $75,146 - $84,106	239 Added 5.06%	4,965 $1.75 Million
Q1 2023 Apr 26, 2023	BUY	$283.23 - $323.1 $7,363 - $8,400	26 Added 0.55%	4,726 $1.49 Million
Q4 2022 Jan 30, 2023	BUY	$285.76 - $321.48 $15,431 - $17,359	54 Added 1.16%	4,700 $1.36 Million
Q3 2022 Nov 01, 2022	BUY	$273.83 - $305.53 $1.27 Million - $1.42 Million	4,646 New	4,646 $1.35 Million

Others Institutions Holding VRTX

# of Institutions

1,833

Shares Held

233M

Call Options Held

1.38M

Put Options Held

1.08M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $114B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Highview Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Highview Capital Management LLC with notifications on news.

Account

Highview Capital Management LLC Vertex Pharmaceuticals Inc Transaction History